

2024-2025 Psychiatry Resident-In-Training Examination (CHILD PRITE) Content Outline

| Domain/Subdomain | Items |
|---|-----------|
| A. Clinical Neurosciences | 20 |
| A.1 Neurodevelopment | 3 |
| A.2 Neuroanatomy | 2 |
| A.3 Neurophysiology | 2 |
| A.4 Genetics | 13 |
| A.4.a Types of genetic abnormalities | 7 |
| A.4.b Methods to identify genes and genetic disorders | 3 |
| A.4.c Epigenetics | 3 |
| B. Clinical Neurology | 20 |
| B.1 Diagnostic procedures | 5 |
| B.1.a Neurological interview and examination | 2 |
| B.1.b Neuroimaging | 2 |
| B.1.c Neurophysiological testing for neurological evaluation | 1 |
| B.2 Diagnostic and clinical evaluation of neurologic disorders/syndromes | 10 |
| B.2.a Common neurological disorders/syndromes | 5 |
| B.2.b Comorbid psychiatric disorders associated with neurological disorders/syndromes | 5 |
| B.3 Management and treatment of neurological disorders/syndromes | 5 |
| C. Clinical Psychiatry | |
| C.1 Development and Maturation | 23 |
| C.1.a Physical | 3 |
| C.1.b Cognitive/Language | 4 |
| C.1.c Psychological/Emotional/Personality | 4 |
| C.1.d Social | 4 |
| C.1.e Sexual | 2 |
| C.1.f Environmental influences | 3 |
| C.1.g Life transitions | 3 |
| C.2 Behavioral and Social Sciences | 12 |
| C.2.a Psychology | 12 |
| C.2.a.1 Behavioral/Cognitive psychology | 3 |
| C.2.a.2 Neuropsychology/Learning theory | 3 |
| C.2.a.3 Psychoanalytic/Psychodynamic theory | 3 |
| C.2.a.4 Social psychology/Sociology/Anthropology/Ethnology | 3 |

| Domain/Subdomain | Items |
|--|-----------|
| C.2.b Other behavioral/social sciences | 0 |
| C.3 Epidemiology | 7 |
| C.3.a Core concepts and major research studies | 3 |
| C.3.b Prevention/Risk Factors/Resilience/Protective factors | 3 |
| C.3.c Other epidemiology | 1 |
| C.4 Diagnostic Procedures | 12 |
| C.4.a Interview | 2 |
| C.4.b Mental Status | 2 |
| C.4.c Diagnostic assessments and rating scales | 2 |
| C.4.d Psychological/Neuropsychological testing | 2 |
| C.4.e Laboratory testing/Monitoring | 1 |
| C.4.f Imaging | 1 |
| C.4.g Neurophysiological testing | 2 |
| C.4.g.1 EEG | 1 |
| C.4.g.2 EMG | 0 |
| C.4.g.3 Sleep | 1 |
| C.4.h Other diagnostic procedures | 0 |
| C.5 Psychopathology and Associated Conditions | 31 |
| C.5.a Disorders | 26 |
| C.5.a.1 Neurodevelopmental | 3 |
| C.5.a.2 Schizophrenia spectrum and other psychotic disorders | 1 |
| C.5.a.3 Bipolar and related disorders | 1 |
| C.5.a.4 Depressive disorders | 3 |
| C.5.a.5 Anxiety disorders | 3 |
| C.5.a.6 Obsessive-compulsive and related disorders | 1 |
| C.5.a.7 Trauma and stressor-related disorders | 2 |
| C.5.a.8 Dissociative disorders | 0 |
| C.5.a.9 Somatic symptom and related disorders | 1 |
| C.5.a.10 Feeding and eating disorders | 1 |
| C.5.a.11 Elimination disorders | 1 |
| C.5.a.12 Sleep-wake disorders | 1 |
| C.5.a.13 Sexual dysfunctions | 0 |
| C.5.a.14 Gender dysphoria | 1 |
| C.5.a.15 Disruptive/Impulse control/Conduct disorders | 2 |
| C.5.a.16 Substance-related and addictive disorders | 2 |
| C.5.a.17 Neurocognitive disorders | 1 |
| C.5.a.18 Personality disorders | 1 |

| Domain/Subdomain | Items |
|--|-----------|
| C.5.a.19 Paraphilic disorders | 0 |
| C.5.a.20 Reproductive Psychopathology | 1 |
| C.5.a.21 Other mental disorders | 0 |
| C.5.b High Risk Behaviors | 5 |
| C.5.b.1 Suicidality/Self-injurious behavior | 2 |
| C.5.b.2 Aggression/Interpersonal violence and homicide/Social aggression | 2 |
| C.5.c Environmental factors | 1 |
| C.6 Treatment | 35 |
| C.6.a Patient Engagement | 1 |
| C.6.b Case Formulation/Differential Diagnosis/Treatment Planning | 1 |
| C.6.c Management of difficult patients and nonadherence to treatment | 1 |
| C.6.d Somatic Therapies | |
| C.6.d.1 Psychopharmacology | 15 |
| C.6.d.1.a Pharmacokinetics/Pharmacodynamics | 1 |
| C.6.d.1.b Drug Interactions | 1 |
| C.6.d.1.c Age/Gender/Racial issues | 1 |
| C.6.d.1.d Pharmacogenomics | 1 |
| C.6.d.1.e Antipsychotics | 1 |
| C.6.d.1.f Antidepressants | 1 |
| C.6.d.1.g Antianxiety/Sedative-hypnotics | 1 |
| C.6.d.1.h Mood stabilizers | 1 |
| C.6.d.1.i Cognitive enhancers | 1 |
| C.6.d.1.j Psychostimulants | 1 |
| C.6.d.1.k Medications to treat substance use | 1 |
| C.6.d.1.l Reproductive Treatment Issues | 1 |
| C.6.d.1.m Augmentation agents | 1 |
| C.6.d.1.n Medications for side effects | 1 |
| C.6.d.1.o Adverse medication effects | 1 |
| C.6.d.1.p Other psychopharmacology | 0 |
| C.6.e Other somatic therapies | 3 |
| C.6.e.1 Neuromodulation | 1 |
| C.6.e.2 Phototherapy/Chronotherapy | 1 |
| C.6.e.3 Complementary/Alternative medicine | 1 |
| C.6.e.4 Other somatic therapies | 0 |
| C.6.f Psychotherapy and Psychoeducational Interventions | 10 |
| C.6.f.1 Supportive | 1 |
| C.6.f.2 Behavioral/Dialectical Behavioral | 1 |



| Domain/Subdomain | Items |
|--|------------|
| C.6.f.3 Cognitive/Cognitive-Behavioral | 1 |
| C.6.f.4 Interpersonal | 1 |
| C.6.f.5 Dyadic | 1 |
| C.6.f.6 Psychoeducation | 1 |
| C.6.f.7 Psychodynamic/Psychoanalytic | 1 |
| C.6.f.8 Family | 1 |
| C.6.f.9 Group | 1 |
| C.6.f.10 Motivational Interviewing | 1 |
| C.6.f.11 Other Psychotherapy/Psychoeducational interventions | 0 |
| C.6.g Psychosocial/Milieu Treatments | 4 |
| C.6.g.1 Rehabilitation/Relapse prevention/Harm reduction | 1 |
| C.6.g.2 Inpatient/Residential | 1 |
| C.6.g.3 Outpatient | 1 |
| C.6.g.4 Emergency/Crisis Interventions | 1 |
| C.6.g.5 Other Psychosocial/Milieu treatments | 0 |
| C.7 Consultation and Collaborative-Integrated Care | 8 |
| C.7.a Medical | 2 |
| C.7.b Court/Justice system | 2 |
| C.7.c Community Mental Health | 1 |
| C.7.d School | 3 |
| C.7.e Other consultation | 0 |
| C.8 Issues in Practice | 16 |
| C.8.a Quality improvement/Patient safety/Risk management/Use of Technology | 5 |
| C.8.b Ethics/Professionalism | 5 |
| C.8.c Forensics/Legal issues | 5 |
| C.8.d History of psychiatry | 1 |
| C.9 Research and Scholarship Literacy | 8 |
| C.9.a Research design/Methods | 3 |
| C.9.b Accessing/Evaluating/Applying evidence to practice | 3 |
| C.9.c Statistics | 2 |
| C.10 Administration and Systems | 8 |
| C.10.a Administration | 4 |
| C.10.b Systems | 4 |
| Total | 200 |